SEC Form 4 · accession 0001209191-17-065786
Forte Biosciences, Inc. · FBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Douglas Jolly
Officer — EVP, Research & Pharm Devel
Period of report
Dec 8, 2017
Accepted (ET)
Dec 14, 2017 · 8:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419041
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 8, 2017 | J | 739 | $8.50 | A | 392,043 | D | |
| Common StockF2 | holding | — | — | — | 21,739 | I | By son | |
| Common StockF2 | holding | — | — | — | 21,739 | I | By daughter |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This Form 4 is being filed voluntarily to report the acquisition of 739 shares by the Reporting Person on December 8, 2017 pursuant to the Issuer's Employee Stock Purchase Plan.
- F2The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.